Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MPL | P40238 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.59 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | RRM1 | P23921 | 2/20 | 0.56 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.56 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.56 |
| ▸ | SCD | O00767 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20512983 | 0.88 | KDM4E (0.69) | KDM4EMEN1MAPTKMT2ARAB9A | |
| SCHEMBL6252757 | 0.85 | ALOX5 (0.67) | KDM4EMEN1MAPTKMT2AMPL | |
| SCHEMBL5732213 | 0.83 | RAB9A (0.70) | KDM4EMEN1MAPTKMT2ARAB9A | |
| SCHEMBL6330254 | 0.82 | MEN1 (0.56) | MEN1MAPTKMT2AMPLNPC1 | |
| SCHEMBL6248973 | 0.81 | MAPT (0.67) | KDM4EMEN1MAPTKMT2AMPL | |
| SCHEMBL16603984 | 0.81 | RAB9A (0.76) | KDM4EMEN1MAPTKMT2ARAB9A | |
| SCHEMBL3341387 | 0.77 | MAPT (0.60) | KDM4EMEN1MAPTKMT2ARAB9A | |
| SCHEMBL7235764 | 0.77 | RAB9A (0.77) | KDM4EMEN1MAPTKMT2ARAB9A | |
| SCHEMBL30581066 | 0.76 | RAB9A (0.78) | KDM4EMEN1MAPTKMT2ARAB9A | |
| SCHEMBL4876734 | 0.76 | MPL (1.00) | MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | KDM4E 4506/4885MEN1 4471/4885MAPT 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.